Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN56,1356,150,86
Msft-1,46
Nokia4,5474,6810,78
IBM-0,43
Mercedes-Benz Group AG56,7656,78-1,11
PFE-0,35
08.02.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 07.02.2025 21:59:29
Dynavax Tech (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
13,15 0,31 0,04 1 155 932
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 09.02.2025
Popis společnosti
Obecné informace
Název společnostiDynavax Technologies Corp
TickerDVAX
Kmenové akcie:Ordinary Shares
RICDVAX.O
ISIN-
Prioritní akciePreference Shares Series B
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.09.2024
Počet zaměstnanců k 31.12.2023 408
Akcie v oběhu k 05.11.2024 131 454 561
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice2100 Powell Street, Suite 720
MěstoEMERYVILLE
PSČ94608
ZeměUnited States
Kontatní osobaNicole Arndt
Funkce kontaktní osobyInvestor Relations
Telefon15 108 485 100
Fax15108481327

Business Summary: Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Dynavax Technologies Corp revenues increased 16% to $205.2M. Net income totaled $20.3M vs. loss of $6.6M. Revenues reflect HEPLISAV-B segment increase of 22% to $197.4M. Net Income reflects Bad debt expense decrease from $12.3M (expense) to $0K, Interest income increase of 25% to $28.1M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.05 to $0.15.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 09.02.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Operating OfficerDavid Novack6216.12.201925.03.2013
Chief Executive Officer, DirectorRyan Spencer4621.05.2019
Chief Financial OfficerKelly MacDonald4001.03.2021
Senior Vice President, General CounselJohn Slebir5828.06.202128.06.2021
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory AffairsRobert Janssen7009.07.2013